Chimeric Infectious Bursal Disease Virus-Like Particles as Potent Vaccines for Eradication of Established HPV-16 E7-Dependent Tumors

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Martin Caballero, Juan ^a   Garzón, Ana ^b,e   González Cintado, Leticia ^c   Kowalczyk, Wioleta ^d,f   Jimenez Torres, Ignacio ^b,g   Calderita, Gloria ^b,h   Rodriguez, Margarita ^b,i   Gondar, Virgínia ^b,j   Bernal, Juan Jose ^b,k   Ardavín, Carlos ^c   Andreu, David ^d   Zürcher, Thomas ^b,l   von Kobbe, Cayetano ^b,m  

^a Barcelona Biomedical Research Park   (Spain)

^b St Louis University (Madrid Campus)   (Spain)

^c CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

^d UNIVERSITAT POMPEU FABRA   (Spain)

^e Azurebio SL   (Spain)

^f CSIRO   (Australia)

^g Igenbiotech   (Spain)

^h NIMGenetics   (Spain)

ⁱ HOSPITAL UNIVERSITARIO HM SANCHINARRO   (Spain)

^j Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas   (Spain)

^k Protein Alternatives SL   (Spain)

^l ForMune S L Vivero de Innovación   (Spain)

^m UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; HUMAN PAPILLOMAVIRUS 16 ONCOPROTEIN VIRUS LIKE PARTICLE E7 VACCINE; PROTEIN E6; PROTEIN E7; UNCLASSIFIED DRUG; WART VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; ERADICATION THERAPY; FEMALE; IMMUNE RESPONSE; INFECTIOUS BURSAL DISEASE VIRUS; MOUSE; NONHUMAN; UTERINE CERVIX CARCINOMA IN SITU; VIRUS LIKE AGENT;

ANIMALS; FEMALE; HUMAN PAPILLOMAVIRUS 16; INFECTIOUS BURSAL DISEASE VIRUS; MICE; MICE, TRANSGENIC; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; VACCINES, VIRUS-LIKE PARTICLE;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; INFECTIOUS BURSAL DISEASE VIRUS; MUS MUSCULUS;

EID: 84871783873     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0052976     Document Type: Article

References (37)

1. International Agency for Research on Cancer (IARC)(2005) Cervix cancer screening. IARC Handbooks of cancer prevention, vol. 10.
2. Hoory T, Monie A, Gravitt P, Wu TC, (2008) Molecular epidemiology of human papillomavirus. J. Formos Med. Assoc. 107: 198-217.
3. Ma B, Xu Y, Hung CF, Wu TC, (2010) HPV and therapeutic vaccines: where are we in 2010? Current Cancer Therapy Reviews 6: 81-103.
4. Herbert J, Coffin J, (2008) Reducing patient risk for human papillomavirus infection and cervical cancer. JAOA 108: 65-70.
5. Hung CF, Monie A, Alvarez RD, Wu TC, (2007) DNA vaccines for cervical cancer: from bench to bedside. Exp. Mol. Med. 39: 679-689.
6. Cid-Arregui A, (2009) Therapeutic vaccines against human papillomavirus and cervical cancer. Open Virol. J. 3: 67-83.
7. Roden R, Wu TC, (2006) How will HPV vaccines affect cervical cancer? Nature Rev. Cancer 6: 753-763.
8. Hirohashi Y, Torigoe T, Inoda S, Kobayasi JI, Nakatsugawa M, et al. (2009) The functioning antigens: beyond just as the immunological targets. Cancer Sci. 100: 798-806.
9. Haigh O, Kattenbelt J, Cochrane M, Thomson S, Gould A, et al. (2010) Hepatitis B surface antigen fusions delivered by DNA vaccination elicit CTL responses to human papillomavirus oncoproteins associated with tumor protection. Cancer Gene Therapy 17: 708-720.
10. Sheng WY, Huang L (2010) Cancer immunotherapy and nanomedicine. Pharm. Res. doi:10.1007/s11095-010-0258-8.
11. Roy P, Noad R, (2008) Virus-like particles as a vaccine delivery system. Human Vaccines 4: 5-8.
12. Jennings GT, Bachmann MF, (2008) The coming of age of virus-like particle vaccines. Biol. Chem. 389: 521-536.
13. Coulibaly F, Chevalier C, Gutsche I, Pous J, Navaza J, et al. (2005) The birnavirus crystal structure reveals structural relationships among icosahedral viruses. Cell 120: 761-772.
14. Garriga D, Querol-Audí J, Abaitua F, Saugar I, Pous J, et al. (2006) The 2.6-Angstrom structure of infectious bursal disease virus-derived T = 1 particles reveals new stabilizing elements of the virus capsid. J. Virol. 80: 6895-6905.
15. Dybing JK, Jackwood DJ, (1998) Antigenic and immunogenic properties of baculovirus-expressed infectious bursal disease viral proteins. Avian Diseases 42: 80-91.
16. Yamaguchi E, Iwata K, Kobayashi M, Ogawa M, Fukushi H, et al. (1996) Epitope mapping of capsid proteins VP2 and VP3 of infectious disease virus. Arch. Virol. 141: 1493-1507.
17. Schreiber TH, Raez L, Rosenblatt JD, Podack ER, (2010) Tumor immunogenicity and responsiveness to cancer vaccine therapy: the state of the art. Seminars in Immunology 22: 105-112.
18. Win SJ, Ward VK, Dunbard PR, Young SL, Baird MA, (2011) Croos-presentation of epitopes on virus-like particles via the MHC I receptor recycling pathway. Immunology and Cell Biology 89: 681-688.
19. Keller SA, von Allmen CE, Hinton HJ, Bauer M, Muntwiler S, et al. (2009) Follicular and marginal zone B cells fail to cross-present MHC Class I-restricted epitopes derived from viral particles. Journal of Immunology 182: 6261-6266.
20. Daftarian PM, Mansour M, Pohajdak B, Fuentes-Ortega A, Korest-Smith E, et al. (2007) Rejection of large HPV-16 expressing tumors in aged mice by a single immunization of VacciMax® encapsulated CTL/T helper peptides. J. of Translational Med. doi:10.1186/1479-5876-5-26.
21. Peng S, Tomson TT, Trimble C, He L, Hung CF, et al. (2006) A combination of DNA vaccines targeting human papillomavirus type 16 E6 and E7 generates potent antitumor effects. Gene Therapy 13: 257-265.
22. Kowalczyk W, Monsó M, de la Torre BG, Andreu D, (2011) Synthesis of multiple antigenic peptides (MAPs)-strategies and limitations. J Pept Sci. 17: 247-251.
23. Feltkamp MCW, Smits HL, Vierboom MPM, Minnaar RP, de Jongh BM, et al. (1993) Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur. J. Immunol. 23: 2242-2249.
24. Ressing ME, Sette A, Brandt RM, Ruppert J, Wentworth PA, et al. (1995) Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J. Immunol. 154: 5934-5943.
25. Dubensky TW, Reed SG, (2010) Adjuvants for cancer vaccines. Seminars in Immunology 22: 155-161.
26. Trincheri G, (2003) Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 3: 133-146.
27. Grohmann U, Fallarino F, Bianchi R, Belladona ML, Vacca C, et al. (2001) IL-6 inhibits the tolerogenic function of CD8 alpha+ dendritic cells expressing indoleamine 2, 3-dioxygenase. J. Immunol. 167: 708-714.
28. Peng S, Frazer IH, Fernando GJ, Zhou J, (1998) Papillomavirus virus-like particles can deliver defined CTL epitopes to the MHC class I pathway. Virology 240: 147-157.
29. Vergati M, Intrivici C, Huen NY, Schlom J, Tsang KY (2010) Strategies for cancer vaccine development. J. of Biomed. Biotech. doi:10.1155/2010/596432.
30. Delgui L, Oña A, Gutierrez S, Luque D, Navarro A, et al. (2009) The capsid protein of infectious bursal disease virus contains a functional alpha 4 beta 1 integrin ligand motif. Virology 386: 360-372.
31. Lenz P, Day PM, Pang YS, Frye SA, Jensen PN, et al. (2001) Papillomavirus-like particles induce acute activation of dendritic cells. J. immunol. 166: 5346-5355.
32. Khatri M, Sharma JM, (2007) Modulation of macrophages by infectious bursal disease virus. Cytogen. and Genome Res. 117: 388-393.
33. Brinkman JA, Xu X, Kast WM, (2007) The efficacy of a DNA vaccine containing inserted and replicated regions of the E7 gene for treatment of HPV-16 induced tumors. Vaccine 25: 3437-3444.
34. Toubaji A, Hill S, Terabe M, Qian J, Floyd T, et al. (2007) The combination of GM-CSF and IL-2 as local adjuvants shows synergy in enhancing peptide vaccines and provides long term tumor protection. Vaccine 25: 5882-5891.
35. Yan Q, Cheung YK, Cheng SC, Xian-Hua W, Shi M, et al. (2007) A DNA vaccine constructed with human papillomavirus type 16 (HPV-16) E7 and E6 genes induced specific immune responses. Gynecologic Oncology 104: 199-206.
36. Smith KA, Meisenburg BL, Tam VL, Pagarigan RR, Wong R, et al. (2009) Lymph node-targeted immunotherapy mediates potent immunity resulting in regression of isolated or metastatic human papillomavirus-transformed tumors. Cancer Therapy 15: 6167-6176.
37. Zhou L, Zhu T, Ye X, Yang L, Wang B, et al. (2010) Long-term protection against HPV E7-positive tumor by a single vaccination of AAV vectors encoding a fusion protein of inactivated E7 of HPV 16/18 and heat shock protein 70. Human Gene Ther. 21: 109-119.